NEW YORK (GenomeWeb News) – Cisbio Bioassays and Blue Sky BioProducts today announced a partnership combining their technologies for the development of assays for target kinases.
The partnership will combine Cisbio's homogenous time resolved fluorescence technology, or HTRF, with Blue Sky's TDA 2.0 technology. TDA 2.0 is a stable solution of lipid-based nanoparticles with nickel-chelating moieties and serves as a template for the assembly of purified His-tagged proteins normally associated with membranes, Cisbio said in a statement.
The deal is expected to result in assays with "unparalleled sensitivity for obtaining better biologically enhanced results on target kinases," Cisbio said.
"Through HTRF, Cisbio Bioassays has developed extensive expertise in the field of kinase enzyme screening tools," said François Degorce, director of marketing and communications for Cisbio. "The combination of these two proven technologies in this area allows us to provide an even more robust and efficient solution for studying these key therapeutic targets, particularly in oncology research."
Based in Worcester, Mass., Blue Sky provides contract research organization services to pharmaceutical firms.
Terms of the deal were not disclosed.